JOHNSON & JOHNSON is 26.8x more valuable than Roivant Sciences Ltd. by market capitalization ($579.83 B vs $21.61 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ROIV | JNJ |
|---|---|---|
| Market cap | $21.61 B | $579.83 B |
| US-listed rank | #599 | #20 |
| Revenue (latest FY) | $8.26M | $94.19B |
| Net income (latest FY) | -$299.77M | $26.80B |
| Net margin | -3629.2% | 28.5% |
| P/E (trailing FY) | - | 21.6 |
| SEC filings | 868 | 984 |
JOHNSON & JOHNSON is 26.8x more valuable than Roivant Sciences Ltd. by market capitalization ($579.83 B vs $21.61 B).
In their latest fiscal years, Roivant Sciences Ltd. reported $8.26M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Roivant Sciences Ltd. and JOHNSON & JOHNSON, or browse the full rankings.